Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
France
France- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
865 trials match your criteria
Recruiting
Systemic scleroderma
RecruitingRegistered drug
Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis
Registered drug
- Disease:Systemic scleroderma
- Substances:Nemolizumab
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Nemolizumab
Recruiting
Non-small cell lung cancer stage I
RecruitingInvestigational
A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer
Investigational
- Disease:Non-small cell lung cancer stage I
- Substances:Mrna-4157Pembrolizumab
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Mrna-4157
Recruiting
Primary progressive multiple sclerosis
RecruitingInvestigational
Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis
Investigational
- Disease:Primary progressive multiple sclerosis
- Substances:–
Countries:France
France- Participants:18–64 years
Recruiting
Colorectal cancer metastatic
RecruitingRegistered drugNo placebo
Study of Sotorasib, Panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.
Registered drugNo placebo
- Disease:Colorectal cancer metastatic
- Substances:BevacizumabCalcium Folinate+4
Countries:France
France- Participants:18–64 years
- Substances:Bevacizumab
Recruiting
Breast cancer
RecruitingRegistered drug
Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer
Registered drug
- Disease:Breast cancer
- Substances:CarboplatinEribulin Mesylate+3
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Carboplatin
Recruiting
Non-small cell lung cancer+1
RecruitingRegistered drugNo placebo
Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC
Registered drugNo placebo
- Disease:Non-small cell lung cancerNon-small cell lung cancer metastatic
- Substances:CarboplatinInfliximab+5
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Carboplatin
Recruiting
Small cell lung cancer+2
RecruitingRegistered drugNo placebo
Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer
Registered drugNo placebo
- Disease:Small cell lung cancerSmall cell lung cancer extensive stage+1
- Substances:AtezolizumabBNT327+3
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
Recruiting
Asthma
RecruitingInvestigational
A Study of Brenipatide Compared to Placebo for Adults with Uncontrolled Moderate to Severe Asthma
Investigational
Countries:France
France- Participants:18–64 years
- Substances:LY3537031
Recruiting
Pancreatic neuroendocrine tumour
RecruitingRegistered drugNo placebo
A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors
Registered drugNo placebo
- Disease:Pancreatic neuroendocrine tumour
- Substances:EverolimusN-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Everolimus
Recruiting
Ischaemic stroke
RecruitingInvestigational
A Study to Test if Rinvecalinase Alfa is Safe and Works for Treating Acute Ischemic Stroke in Patients with Moderate Stroke Severity
Investigational
- Disease:Ischaemic stroke
- Substances:–
Countries:France
France- Participants:18–64 years · 65+ years
Recruiting
Bladder transitional cell carcinoma
RecruitingRegistered drugNo placebo
Study of nadofaragene firadenovec alone or with gemcitabine, docetaxel or pembrolizumab in adults with non-muscle invasive bladder cancer who did not respond to BCG therapy
Registered drugNo placebo
- Disease:Bladder transitional cell carcinoma
- Substances:DocetaxelPembrolizumab+2
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Docetaxel